Acromegaly and hypertension

Abstract

Abstract: Acromegaly is usually caused by pituitary adenomas that secrete growth hormone (GH). The disease is prone to be complicated with hypertension and thus aggravates the state of the illness and increase the disease burden. This paper summarized the prevalence, clinical characteristics, pathophysiological mechanism, diagnosis and treatment of hypertension in patients with acromegaly and potential influence of the disease control on acromegaly on hypertension, in order to deepen the understanding of the disease and provide evidence for good prevention and control of hypertension in patients with acromegaly.

Key words: acromegaly, hypertension, growth hormone, insulin-like growth factor-1(IGF-1)

CLC Number:

WANG Shu-chang, ZHU Hui-juan, PAN Hui. Acromegaly and hypertension[J]. Basic & Clinical Medicine, 2021, 41(9): 1366-1370.

References

[1]Ritvonen E, Loyttyniemi E, Jaatinen P, et al. Mortality in acromegaly: a 20-year follow-up study[J]. Endocr Relat Cancer, 2016, 23: 469-480.
[2]Puglisi S, Terzolo M. Hypertension and acromegaly[J]. Endocrinol Metab Clin North Am, 2019, 48: 779-793.
[3]Minniti G, Moroni C, Jaffrain-Rea M L, et al. Prevalence of hypertension in acromegalic patients: clinical measurement versus 24-hour ambulatory blood pressure monitoring[J]. Clin Endocrinol (Oxf), 1998, 48: 149-152.
[4]Costenaro F, Martin A, Horn RF, et al. Role of ambulatory blood pressure monitoring in patients with acromegaly[J]. J Hypertens, 2016, 34: 1357-1363.
[5]Melmed S, Casanueva FF, Klibanski A, et al. A con-sensus on the diagnosis and treatment of acromegaly complications[J]. Pituitary, 2013, 16: 294-302.
[6]Terzolo M, Matrella C, Boccuzzi A, et al. Twenty-four hour profile of blood pressure in patients with acromegaly. Correlation with demographic, clinical and hormonal features[J]. J Endocrinol Invest, 1999, 22: 48-54.
[7]Sardella C, Urbani C, Lombardi M, et al. The beneficial effect of acromegaly control on blood pressure values in normotensive patients[J]. Clin Endocrinol (Oxf), 2014, 81: 573-581.
[8]Ramos-Levi AM, Marazuela M. Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management[J]. Endocrine, 2017, 55: 346-359.
[9]Arosio M, Reimondo G, Malchiodi E, et al. Predictors of morbidity and mortality in acromegaly: an Italian survey[J]. Eur J Endocrinol, 2012, 167: 189-198.
[10]Vitale G, Pivonello R, Auriemma RS, et al. Hyperten-sion in acromegaly and in the normal population: prevalence and determinants[J]. Clin Endocrinol (Oxf), 2005, 63: 470-476.
[11]Schutte AE, Volpe M, Tocci G, et al. Revisiting the relationship between blood pressure and insulin-like growth factor-1[J]. Hypertension, 2014, 63: 1070-1077.
[12]Powlson AS, Gurnell M. Cardiovascular disease and sleep-disordered breathing in acromegaly[J]. Neuroendocrinology, 2016, 103: 75-85.
[13]Sardella C, Cappellani D, Urbani C, et al. Disease activity and lifestyle influence comorbidities and cardiovascular events in patients with acromegaly[J]. Eur J Endocrinol, 2016, 175: 443-453.
[14]Kamenicky P, Blanchard A, Frank M, et al. Body fluid expansion in acromegaly is related to enhanced epithelial sodium channel (ENaC) activity[J]. J Clin Endocrinol Metab, 2011, 96: 2127-2135.
[15]Thomas J, Dattani A, Zemrak F, et al. Renin-angioten-sin system blockade improves cardiac indices in acro-megaly patients[J]. Exp Clin Endocrinol Diabetes, 2017, 125: 365-367.
[16]Carmichael JD, Broder MS, Cherepanov D, et al. Long-term treatment outcomes of acromegaly patients presenting biochemically-uncontrolled at a tertiary pituitary center[J]. BMC Endocr Disord, 2017, 17: 49.doi:10.1186/s12902-017-0199-x.
[17]Gonzalez B, Vargas G, de Los MA, et al. Persistence of diabetes and hypertension after multimodal treatment of acromegaly[J]. J Clin Endocrinol Metab, 2018, 103: 2369-2375.
[18]Ioachimescu AG. Impact of acromegaly treatment on cardiovascular complications[J]. Endocrine, 2017, 55: 659-661.
[19]Auriemma RS, Grasso LF, Galdiero M, et al. Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly[J]. Endocrine, 2017, 55: 872-884.
[20]Annamalai AK, Webb A, Kandasamy N, et al. A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy[J]. J Clin Endocrinol Metab, 2013, 98: 1040-1050.
[21]Colao A. The GH-IGF-I axis and the cardiovascular system: clinical implications[J]. Clin Endocrinol (Oxf), 2008, 69: 347-358.
[22]Colao A, Bronstein MD, Freda P, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study[J]. J Clin Endocrinol Metab, 2014, 99: 791-799.
[23]Kuhn E, Maione L, Bouchachi A, et al. Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study[J]. Eur J Endocrinol, 2015, 173: 693-702.
[24]Kasuki L, Vieira NL, Gadelha MR. Cabergoline treatment in acromegaly: cons[J]. Endocrine, 2014, 46: 220-225.
[25]Ntali G, Karavitaki N. Efficacy and complications of pituitary irradiation[J]. Endocrinol Metab Clin North Am, 2015, 44: 117-126.